Approval · Notice of Compliance 19020 · 2017
TAGRISSO: Notice of Compliance 19020
Issued March 3, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19020
- Date
- March 3, 2017
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New supplier of the starting material
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TAGRISSO | Not yet assigned | — |
Medicinal ingredients
- OSIMERTINIB 40 MG per TAB
- OSIMERTINIB 80 MG per TAB